Considering the potential impact of immunogenicity on the efficacy and safety of TNFi, wide variation in the prevalence of ADAs across inflammatory diseases, and the paucity of data regarding immunogenicity in Behçet syndrome, we aimed to investigate the prevalence of ADAs against IFX in patients with Behçet syndrome together with suitable controls. This evidence concerns the gene AGPS and Behcet disease.